Pacira Pharmaceuticals Inc (PCRX)

Operating profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Operating income (ttm)	US$ in thousands	87,675	44,614	48,182	39,540	60,024	74,128	84,272	87,880	89,924	104,495	90,682	48,692	46,349	29,281	14,074	26,496	10,481	21,029	22,664	23,930
Revenue (ttm)	US$ in thousands	638,707	621,403	618,553	613,360	627,091	646,604	609,214	577,203	541,534	491,997	489,092	436,030	429,647	421,097	408,298	435,397	421,026	393,717	372,480	353,983
Operating profit margin		13.73%	7.18%	7.79%	6.45%	9.57%	11.46%	13.83%	15.23%	16.61%	21.24%	18.54%	11.17%	10.79%	6.95%	3.45%	6.09%	2.49%	5.34%	6.08%	6.76%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $87,675K ÷ $638,707K
= 13.73%

Pacira BioSciences Inc's operating profit margin has shown fluctuations over the past eight quarters. In Q1 2022, the operating profit margin was at its highest at 22.96%, indicating strong operational efficiency and profitability during that period. However, the operating profit margin gradually decreased over the following quarters, reaching its lowest point of 8.70% in Q1 2023.

Although there was a slight improvement in Q2 and Q3 2023 with operating profit margins of 10.21% and 10.15% respectively, the margins have not yet returned to the levels seen in Q2 2022 and Q1 2022. This downward trend in operating profit margin suggests potential challenges in managing costs or generating revenue efficiently.

Overall, Pacira BioSciences Inc's operating profit margin has been somewhat volatile, and it may be important for stakeholders to closely monitor the company's operational performance to ensure sustainable profitability in the future.